BBIO BridgeBio Pharma

BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET

BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET

PALO ALTO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its first quarter 2026 financial results and business update after the market closes on Thursday, May 7, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.

To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at . A replay of the webcast will be available on the BridgeBio website for 30 days following the event.

Participants may access the webcast by registering online using the following link, .

About BridgeBio Pharma, Inc.

BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit and follow us on , , , , , and .

BridgeBio Media Contact:

Bubba Murarka, Executive Vice President

  

(650)-789-8220

BridgeBio Investor Contact:

Chinmay Shukla, Senior Vice President, Strategic Finance



EN
30/04/2026

Underlying

BBIOBridgeBio Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BridgeBio Pharma

 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio to Report First Quarter 2026 Financial Results and Commercia...

BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET PALO ALTO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its first quarter 2026 financial results and business update after the market closes on Thursday, May 7, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access ...

2h / 10m 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio Launches Health Education Effort on Often Overlooked Heart C...

BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White - New national campaign encourages recognition of ATTR-CM, often mistaken for other heart conditions, where earlier diagnosis and treatment may help improve outcomes PALO ALTO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”), a biopharmaceutical company focused on developing medicines for genetic conditions, has teamed up with award-winning actor Morgan Fre...

April 28, 2026 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5...

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on April 18, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 33 new employees in restricted stock units for an aggregate of 67,247 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock uni...

April 22, 2026 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascu...

Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54 - Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p

March 30, 2026 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with L...

BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9 - Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418’s rapid, consistent treatment effect and favorable safety profile, with statistically significant and clinically meaningful improvements in ambulation and pulmonary function - Based on ongoing discussions with the FDA, BridgeBio anticipates approval with a U.S. launch anticipated in late 2026/early 2027 - If approved, BBP-418 has the potential to become the first and only therapy for individuals living with LGMD2I/R9 and may ...

March 30, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch